Genmab starts Phase II of HuMax-CD4

Genmab (CSE:GEN; NMarkt:GE9D) began a placebo-controlled Phase II trial of its HuMax-CD4 human antibody in combination with methotrexate to treat rheumatoid arthritis (RA). ...